A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin plus granulocyte colony-stimulating factor: significant effects on quality of life
(2003) In British Journal of Haematology 120(6). p.1037-1046- Abstract
- We have published previously a prototype of a decision model for anaemic patients with myelodysplastic syndromes (MDS), in which transfusion need and serum erythropoietin (S-Epo) were used to define three groups with different probabilities of erythroid response to treatment with granulocyte colony-stimulating factor (G-CSF) + Epo. S-Epo less than or equal to 500 U/l and a transfusion need of < 2 units/month predicted a high probability of response to treatment, S-Epo > 500 U/l and greater than or equal to 2 units/month for a poor response, whereas the presence of only one negative prognostic marker predicted an intermediate response. A total of 53 patients from a prospective study were included in our evaluation sample. Patients... (More)
- We have published previously a prototype of a decision model for anaemic patients with myelodysplastic syndromes (MDS), in which transfusion need and serum erythropoietin (S-Epo) were used to define three groups with different probabilities of erythroid response to treatment with granulocyte colony-stimulating factor (G-CSF) + Epo. S-Epo less than or equal to 500 U/l and a transfusion need of < 2 units/month predicted a high probability of response to treatment, S-Epo > 500 U/l and greater than or equal to 2 units/month for a poor response, whereas the presence of only one negative prognostic marker predicted an intermediate response. A total of 53 patients from a prospective study were included in our evaluation sample. Patients with good or intermediate probability of response were treated with G-CSF + Epo. The overall response rate was 42% with 28.3% achieving a complete and 13.2% a partial response to treatment. The response rates were 61% and 14% in the good and intermediate predictive groups respectively. The model retained a significant predictive value in the evaluation sample (P < 0.001). Median duration of response was 23 months. Scores for global health and quality of life (QOL) were significantly lower in MDS patients than in a reference population, and fatigue and dyspnoea was significantly more prominent. Global QOL improved in patients responding to treatment (P = 0.01). The validated decision model defined a subgroup of patients with a response rate of 61% (95% confidence interval 48-74%) to treatment with G-CSF + Epo. The majority of these patients have shown complete and durable responses. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/316320
- author
- organization
- publishing date
- 2003
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- granulocyte colony-stimulating factor, anaemia, erythropoietin, myelodysplasia
- in
- British Journal of Haematology
- volume
- 120
- issue
- 6
- pages
- 1037 - 1046
- publisher
- Wiley-Blackwell
- external identifiers
-
- wos:000181633900015
- pmid:12648074
- scopus:0037353935
- ISSN
- 0007-1048
- DOI
- 10.1046/j.1365-2141.2003.04153.x
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Division of Hematology and Transfusion Medicine (013041100), Emergency medicine/Medicine/Surgery (013240200)
- id
- eb6e71e7-d008-47da-87e6-57076c7f7886 (old id 316320)
- date added to LUP
- 2016-04-01 11:35:42
- date last changed
- 2024-10-23 03:25:59
@article{eb6e71e7-d008-47da-87e6-57076c7f7886,
abstract = {{We have published previously a prototype of a decision model for anaemic patients with myelodysplastic syndromes (MDS), in which transfusion need and serum erythropoietin (S-Epo) were used to define three groups with different probabilities of erythroid response to treatment with granulocyte colony-stimulating factor (G-CSF) + Epo. S-Epo less than or equal to 500 U/l and a transfusion need of < 2 units/month predicted a high probability of response to treatment, S-Epo > 500 U/l and greater than or equal to 2 units/month for a poor response, whereas the presence of only one negative prognostic marker predicted an intermediate response. A total of 53 patients from a prospective study were included in our evaluation sample. Patients with good or intermediate probability of response were treated with G-CSF + Epo. The overall response rate was 42% with 28.3% achieving a complete and 13.2% a partial response to treatment. The response rates were 61% and 14% in the good and intermediate predictive groups respectively. The model retained a significant predictive value in the evaluation sample (P < 0.001). Median duration of response was 23 months. Scores for global health and quality of life (QOL) were significantly lower in MDS patients than in a reference population, and fatigue and dyspnoea was significantly more prominent. Global QOL improved in patients responding to treatment (P = 0.01). The validated decision model defined a subgroup of patients with a response rate of 61% (95% confidence interval 48-74%) to treatment with G-CSF + Epo. The majority of these patients have shown complete and durable responses.}},
author = {{Hellstrom-Lindberg, E and Gulbrandsen, N and Lindberg, G and Ahlgren, T and Dahl, IMS and Dybedal, I and Grimfors, G and Hesse-Sundin, E and Hjorth, M and Kanter-Lewensohn, L and Linder, O and Luthman, M and Lofvenberg, E and Oberg, G and Porwit-MacDonald, A and Radlund, A and Samuelsson Johannesson, Jannica and Tangen, JM and Winquist, I and Wisloff, F}},
issn = {{0007-1048}},
keywords = {{granulocyte colony-stimulating factor; anaemia; erythropoietin; myelodysplasia}},
language = {{eng}},
number = {{6}},
pages = {{1037--1046}},
publisher = {{Wiley-Blackwell}},
series = {{British Journal of Haematology}},
title = {{A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin plus granulocyte colony-stimulating factor: significant effects on quality of life}},
url = {{http://dx.doi.org/10.1046/j.1365-2141.2003.04153.x}},
doi = {{10.1046/j.1365-2141.2003.04153.x}},
volume = {{120}},
year = {{2003}},
}